CURRICULUM VITAE Michael P
Total Page:16
File Type:pdf, Size:1020Kb
CURRICULUM VITAE Michael P. Pollastri, Ph.D. Northeastern University Department of Chemistry & Chemical Biology 102 Hurtig Hall; 360 Huntington Avenue Boston, MA 02115 USA (617) 373 2703; [email protected] http://www.northeastern.edu/pollastri Education Brown University, Providence, RI Ph.D., Organic Chemistry, May 2004 Research Director: Kathlyn A. Parker, Ph.D., Professor of Chemistry Dissertation title: “Applications of ruthenium-catalyzed olefin metathesis to the preparation of fused ring systems” Duke University, Durham, NC M.S., Organic Chemistry, May 1998 Research Director: Ned A. Porter, Ph.D., James B. Duke Professor of Chemistry College of the Holy Cross, Worcester, MA A.B., With Honors in Chemistry, May 1995 Research Director: Timothy P. Curran, Ph.D., Associate Professor of Chemistry Scientific Employment 2009- Northeastern University Department of Chemistry & Chemical Biology Professor (2017-) Department Chair (2016-) Interim Director, Barnett Institute for Chemical and Biological Analysis (2016-) Associate Professor, (2009-2017) 2015- Northeastern University Department of Bioengineering Affiliated Associate Professor 2010-2011 Boston University Department of Medicine, Boston, MA Adjunct Assistant Professor of Medicine 2007-2009 Boston University Department of Chemistry, Boston, MA Research Assistant Professor of Chemistry (2007-2009) Founding Director, Medicinal Chemistry & Core Synthesis Facility (2007-2009) Founding Director, Center for Molecular Discovery (2008-2009) 2006-2011 Brandeis University, Rabb School of Continuing Studies, Waltham, MA. Instructor 2003-2007 Pfizer Global Research & Development, Cambridge, MA Principal Scientist & Head of Chemical Technologies (2005-2007) Senior Scientist – Medicinal Chemistry (2003-2005) 1998-2003 Pfizer Global Research & Development, Groton, CT Associate Scientist (2003) Assistant Scientist (1998-2003) Awards & Honors Northeastern University Pre-Medical Program “Golden Pen” Award, 2017 Department of Residential Life Faculty Member of the Year nominee, 2016 Class of 2013 “Faculty Favorite” Nominated, Excellence in Teaching Award, 2013 University Excellence in Teaching Award, 2012 Department of Chemistry Service Award, 2012 Pfizer, Inc. RTC Blaze of Glory Award, 2005 Global R&D Achievement Award, 2003 Global R&D Excellence Award, 2003 Green Chemistry Award, 2003 Discovery - Above & Beyond Award, 2001, 2002 Phi Lambda Upsilon, Chemistry Honor Society, 1996 Joseph Cahill Award for Excellence in Chemistry (College of the Holy Cross), 1995 Research PUBLICATIONS Peer-reviewed publications. All last-author publications were also corresponding author. †NU undergraduate student advised by MPP; ‡NU graduate student advised or co-advised by MPP; ºpostdoctoral scholar supervised by MPP. 1. Absalon, S.; Blomqvist, K.; Rudlaff, R.; †DeLano, T.J.; Pollastri, M.P.; Dvorin, J.D. Calcium- dependent protein kinase 5 is required for release of egress-specific organelles in Plasmodium falciparum. Proceedings of the National Academy of Sciences. Revision Submitted. 2. Mehta, N.; Ferrins, L.; Leed, S.E.; Sciotti, R.J.; Pollastri, M.P. Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation. ACS Infectious Diseases, Submitted 3. ‡Klug, D.M.; Diaz-Gonazalez, R.; Perez-Moreno, G.; Ceballos-Perez, G.; Garcia-Hernandez, R.; Gomez-Perez, V.; Ruiz-Perez, L.; Gamarro, F.; Gonzalez-Pacanowska, D.; Navarro, M.; Pollastri, M.P. Early evaluation of a class of isatinoid inhibitors identified from a high-throughput screen of anti-sleeping sickness agents. Bioorganic & Medicinal Chemistry Letters, Under Revision. 4. Ferrins, L.; Pollastri, M.P. The importance of collaboration between industry, academics, and non- profits in tropical disease drug discovery ACS Infectious Diseases, In Press. Invited, peer reviewed perspective article. 5. ‡Woodring, J.L.; ‡Bachovchin, K.A.; †Brady, K.G.; †Gallerstein, M.F.; Erath, J.; Tanghe, S.; Leed, S.E.; Rodriguez, A.; Mensa-Wilmot, K.; Sciotti, R.J.; Pollastri, M.P. Towards Optimized Physicochemical Properties for 4-Anilinoquinazoline Inhibitors of Trypanosome Proliferation. European Journal of Medicinal Chemistry, 2017, 141, 446-459. 6. ‡Yuan, G.; Jankins, T.C.; Patrick, C.G.; Philbrook, P.; Sears, O.; Hatfield, S.; Sitovsky, M.; Vasdev, N.; Liang, S.H.; Ondrechen, M.J.; Pollastri, M.P.; Jones, G.B. Fluorinated adenosine A2a receptor antagonists inspired by preladenant as potential cancer immunotherapeutics. International Journal of Medicinal Chemistry, doi:10.1155/2017/4852537. 7. Kunz, S.; Balmer, V.; Sterk, G.J.; Pollastri, M.P.; Leurs, R.; Muller, N.; Hemphill, A.; Spycher, C. The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target. PLOS Neglected Tropical Diseases, 2017, 11, e0005981. 8. ‡Devine, W.; Thomas, S.; Erath, J.; ‡Bachovchin, K.; Lee, P.; Leed, S.; Rodriguez, A.; Sciotti, R.J.; Mensa-Wilmot, K.; Pollastri, M.P. Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites. ACS Medicinal Chemistry Letters, 2017, 8, 350. ACS Editors’ Choice Article 9. ‡Devine, W.; Diaz-Gonzalez, R.; Ceballos-Perez, G.; Rojas, D.; Satoh, T.; ‡Tear, W.; Ranade, R.M.; Barros-Alvarez, X.; Hol, W.G.J.; Buckner, F.S.; Navarro, M.; Pollastri, M.P. From cells, to mice, to target: Characterization of NEU-1053 (SB-443342) and its analogs for treatment of human African trypanosomiasis. ACS Infectious Diseases, 2017, 3, 225. 10. Guyett, P.; Behera, R.; Ogata, Y.; Pollastri, M.P.; Mensa-Wilmot, K Novel Effects of Lapatinib Revealed in the African Trypanosome using Hypothesis-Generating Proteomics and Chemical Biology Strategies. Antimicrobial Agents and Chemotherapy, 2017, 61, e01865. 11. Thomas, S.M.; Purmal, A.; Pollastri, M.P.; Mensa-Wilmot, K. Discovery of a carbazole-derived lead drug for human African trypanosomiasis. Scientific Reports, 2016, 6, 32083. 12. Guyett, P.J.; Xia, S.; Swinney, D.; Pollastri, M.P.; Mensa-Wilmot, K. Glycogen Synthase Kinase 3β Promotes Endocytosis of Transferrin in the African Trypanosome. ACS Infectious Diseases, 2016, 2, 518-528. 13. ‡Klug, D.M.; Gelb, M.H.; Pollastri, M.P. Repurposing Strategies for Neglected Disease Drug Discovery. Bioorganic and Medicinal Chemistry Letters (Digest). 2016, 26, 2569-2576. Invited article 14. ºAmata, E.; Xi, H.; Colmenarejo, G.; Gonzalez-Diaz, R.; Cordon-Obras, C.; Berlanga, M.; Manzano, P.; Erath, J.; Roncal, N.E.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Sciotti, R.J.; Navarro, M.; Pollastri, M.P. identification of “preferred” human kinase inhibitors for sleeping sickness lead discovery. Are some kinases better than others for inhibitor repurposing? ACS Infectious Diseases, 2016, 2, 180-186. 15. ‡Devine, W.; ‡Woodring, J.L.; ‡Swaminathan, U.; ºAmata, E.; ºPatel, G.; Erath, J.; Roncal, R.E.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Mensa-Wilmot, K.; Sciotti, R.J.; Pollastri, M.P. Protozoan parasite growth inhibitors discovered by cross-screening yields potent scaffolds for lead discovery. Journal of Medicinal Chemistry 2015, 58, 5522-5537. 16. ºAmata, E.; Bland, N.D.; Campbell, R.K.; Pollastri, M.P. Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). Tetrahedron Letters. 2015, 56, 2832-2835. 17. Kozakov, K.; Hall, D.R.; Jehle, S.; Luo, L.; ‡Ochiana, S.O.; †Jones, E.V.; Pollastri, M.P.; Allen, K.N.; Whitty, A.; Vajda, S. Ligand Deconstruction: Why Some Fragment Binding Positions Are Conserved and Others Are Not. Proceedings of the National Academy of Science 2015, 112, E2585-E2594. 18. Shivanna S.; Kolandaivelu, K.; Moshe, S.; Novikov, O.; Balcells, M.; Zheng A.; Weinberg, J.; Francis, J.; Pollastri, M.P.; Edelman, E.R.; Sherr, D.H.; Chitalia, V.C. The aryl hydrocarbon receptor is a critical regulator of tissue factor stability and is a novel anti-thrombotic target in uremia. Journal of the American Society of Nephrology. In Press. doi: 10.1681/ASN.2014121241 19. ‡Ochiana, S.O.; Bland, N.D.; Settimo, L.; Campbell, R.K.; Pollastri, M.P. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. Chemical Biology & Drug Design 2015, 85, 549-564. 20. ‡Woodring, J.L.; oPatel, G.; Erath, J.; Behera, R.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Sciotti, R.J.; Mensa-Wilmot, K.; Pollastri, M.P. Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria. MedChemComm. 2015, 6, 339-346. 21. ‡Silva, L.; ‡Tanner, A.; Merritt, C.; Stuart, K.; Pollastri, M.P. Protein kinases as druggable targets in protozoan parasites. Chemical Reviews, 2014, 114, 1280–11304. Invited review. 22. Diaz, R.; ºLuengo-Arratta, S.A.; ºSeixas, J.D.; ºAmata, E.; ‡Devine, W.; Cordon-Obras, C.; Rojas- Barros, D.I.; Jimenez, E.; Ortega, F.; Crouch, S.; Colmenarejo, G.; Fiandor, J.M.; Martin, J.J.; Berlanga, M.; Gonzalez, S.; Manzano, P.; Navarro, M.; Pollastri, M.P. Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign. PLOS Neglected Tropical Diseases. 2014, 8, e3253. 23. Parks, A.J.; Pollastri, M.P.; Hahn, M.E.; Stanford, E.A.; Franks, D.G; Haigh, S.E.; Narasimhan, S.; ºAshton, T.D.; †Hopper, T.G.; Kozakov, D.; Beglov, D.; Vajda, S.; Schlezinger, J.J.; Sherr, D.H. In Silico Identification of an Aryl Hydrocarbon